Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue Estimates
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.60 per share, beating the Zacks Consensus Estimate of $5.79 per share. This compares to earnings of $5.02 per share a year ago.
Jazz (JAZZ) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Get a deeper insight into the potential performance of Jazz (JAZZ) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Jazz (JAZZ) Surges 5.2%: Is This an Indication of Further Gains?
Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Jazz Pharmaceuticals: Should Sing A Better Tune In 2025
Jazz Pharmaceuticals' stock moved nicely higher post-3Q24 report and FDA approval of zanidatamab, despite challenges in its narcolepsy franchise from Avadel's Lumryz. Jazz's neuroscience franchise faces declining Xyrem sales but sees growth in Xywav and Epidiolex. Oncology growth is driven by zanidatamab's approval and other key drugs like Rylaze and Zepzelca, crucial for achieving Vision 2025 sales goals.
Wall Street Analysts Think Jazz (JAZZ) Could Surge 44.37%: Read This Before Placing a Bet
The consensus price target hints at a 44.4% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer
Following the FDA's approval, Jazz's Ziihera becomes the first dual HER2-targeted bispecific antibody and chemotherapy-free treatment approved for biliary tract cancer.
Jazz Pharmaceuticals receives FDA approval for biliary tract cancer treatment
The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' drug, zanidatamab-hrii, for the treatment of a type of biliary tract cancer, the company said on Wednesday.
Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is the Options Market Predicting a Spike in Jazz (JAZZ) Stock?
Investors need to pay close attention to Jazz (JAZZ) stock based on the movements in the options market lately.
Jazz (JAZZ) Upgraded to Buy: Here's Why
Jazz (JAZZ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
JAZZ or CTLT: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Drugs stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). But which of these two stocks is more attractive to value investors?
